Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date

被引：26
|
作者：
Montemorano, Lauren [1 ]
Lightfoot, Michelle D. S. [2 ]
Bixel, Kristin [2 ]
机构：
[1] Ohio State Univ, Dept Obstet & Gynecol, Wexner Med Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, James Canc Hosp, Dept Obstet & Gynecol,Div Gynecol Oncol, Columbus, OH 43210 USA
来源：
ONCOTARGETS AND THERAPY | 2019年 / 12卷
关键词：
olaparib; PARP inhibitor; ovarian cancer; maintenance; DOUBLE-BLIND; THERAPY; CHEMOTHERAPY; BEVACIZUMAB; INHIBITORS; CARCINOMA;
D O I：
10.2147/OTT.S195552
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have received multiple prior lines of chemotherapy. In this review, we focus on the use of olaparib in the maintenance setting including the evidence to date, ongoing research, and future directions.
引用
收藏
页码：11497 / 11506
页数：10
相关论文
共 50 条
  • [1] Olaparib maintenance for first-line treatment of ovarian cancer:will SOLO1 reset the standard of care?
    Miller, Rowan E.
    Crusz, Shanthini M.
    Ledermann, Jonathan A.
    FUTURE ONCOLOGY, 2019, 15 (16) : 1845 - 1853
  • [2] Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
    Ledermann, Jonathan A.
    Pujade-Lauraine, Eric
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [3] Olaparib in the treatment of ovarian cancer
    Washington, Christina R.
    Richardson, Debra L.
    Moore, Kathleen N.
    FUTURE ONCOLOGY, 2019, 15 (30) : 3435 - 3449
  • [4] Olaparib for the treatment of epithelial ovarian cancer
    McLachlan, Jennifer
    Banerjee, Susana
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (07) : 995 - 1003
  • [5] Latest clinical evidence of maintenance therapy in ovarian cancer
    Walsh, Christine S.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2020, 32 (01) : 15 - 21
  • [6] OLAPARIB FOR THE TREATMENT OF OVARIAN CANCER
    Bornstein, E.
    Jimeno, A.
    DRUGS OF TODAY, 2016, 52 (01) : 17 - 28
  • [7] Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
    Moore, K.
    Colombo, N.
    Scambia, G.
    Kim, B. -G.
    Oaknin, A.
    Friedlander, M.
    Lisyanskaya, A.
    Floquet, A.
    Leary, A.
    Sonke, G. S.
    Gourley, C.
    Banerjee, S.
    Oza, A.
    Gonzalez-Martin, A.
    Aghajanian, C.
    Bradley, W.
    Mathews, C.
    Liu, J.
    Lowe, E. S.
    Bloomfield, R.
    DiSilvestro, P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26) : 2495 - 2505
  • [8] Frontline Maintenance Treatment for Ovarian Cancer
    Elyashiv, Osnat
    Wong, Yien Ning Sophia
    Ledermann, Jonathan A.
    CURRENT ONCOLOGY REPORTS, 2021, 23 (08)
  • [9] PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies
    Bahena-Gonzalez, Antonio
    Toledo-Leyva, Alfredo
    Gallardo-Rincon, Dolores
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (04)
  • [10] The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer
    Nirsimloo, Rachel
    Gourley, Charlie
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (06) : 597 - 603
12345